Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Add-on Pilot Trial of Minocycline to Treat Fragile X Syndrome

This study has been completed.
Sponsor:
Collaborator:
Fragile X Research Foundation of Canada
Information provided by (Responsible Party):
FRAXA Research Foundation
ClinicalTrials.gov Identifier:
NCT00858689
First received: March 9, 2009
Last updated: February 16, 2016
Last verified: February 2016
  Purpose
Fragile X Syndrome (FXS) is the most common known inherited form of mental impairment, developmental disability and autism. Minocycline is an antibiotic that has recently been used to treat the mouse model for Fragile X, and was found to reverse the structural abnormalities that are seen their brain cells. The purpose of this research study is to determine if minocycline is an effective treatment for patients with fragile X syndrome (FXS).

Condition Intervention
Fragile X Syndrome
Drug: Minocycline

Study Type: Interventional
Study Design: Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Add-on Pilot Trial of Minocycline in Fragile X Syndrome

Resource links provided by NLM:


Further study details as provided by FRAXA Research Foundation:

Primary Outcome Measures:
  • Change From Baseline of ABC Irritability Subtest Score at 8 Weeks [ Time Frame: Baseline and 8 weeks ] [ Designated as safety issue: No ]
    The 15-item Irritability Scale includes questions about aggression, self-injury, tantrums, agitation, and unstable mood on a scale of 0 to 45 with higher scores indicating greater severity. This scale has been successfully used in previous medication studies in children with autism and in patients with FXS and in a controlled trial of ampakine CX516 in FXS. All ABC subscales showed good reliability when used by parents and caregivers of individuals with FXS to assess behavior in the CX516 study NCT00054730, and yielded intraclass correlation coefficient (ICC) values of 0.7-0.9.

  • ABC Irritability Subtest Score [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
    ABC Irritability subtest score was used

  • ABC Irritability Subtest Score [ Time Frame: 1 year ] [ Designated as safety issue: No ]
    ABC (Aberrant behavior checklist) Irritability subtest score was used


Secondary Outcome Measures:
  • Parent Defined Target Symptoms Scale-Visual [ Time Frame: Baseline ] [ Designated as safety issue: No ]
  • Clinical Global Impression Scale [ Time Frame: Baseline ] [ Designated as safety issue: No ]
  • Stanford Binet 5 (SB5) [ Time Frame: Baseline ] [ Designated as safety issue: No ]
  • The Peabody Picture Vocabulary Test Third Edition (PPVT-III) [ Time Frame: Baseline ] [ Designated as safety issue: No ]
  • The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) [ Time Frame: Baseline ] [ Designated as safety issue: No ]
  • Non-Verbal Associative Learning Task (NVALT) [ Time Frame: Baseline ] [ Designated as safety issue: No ]
  • Vineland Adaptive Behaviour Scales (VABS) [ Time Frame: Baseline ] [ Designated as safety issue: No ]
  • Parent Defined Target Symptoms Scale-Visual [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
  • Parent Defined Target Symptoms Scale-Visual [ Time Frame: 1 year ] [ Designated as safety issue: No ]
  • Clinical Global Impression Scale [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
  • Clinical Global Impression Scale [ Time Frame: 1 year ] [ Designated as safety issue: No ]
  • Stanford Binet 5 (SB5) [ Time Frame: 1 year ] [ Designated as safety issue: No ]
  • The Peabody Picture Vocabulary Test Third Edition (PPVT-III) [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
  • The Peabody Picture Vocabulary Test Third Edition (PPVT-III) [ Time Frame: 1 year ] [ Designated as safety issue: No ]
  • The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
  • The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) [ Time Frame: 1 year ] [ Designated as safety issue: No ]
  • Non-Verbal Associative Learning Task (NVALT) [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
  • Non-Verbal Associative Learning Task (NVALT) [ Time Frame: 1 year ] [ Designated as safety issue: No ]
  • Vineland Adaptive Behaviour Scales (VABS) [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
  • Vineland Adaptive Behaviour Scales (VABS) [ Time Frame: 1 year ] [ Designated as safety issue: No ]

Enrollment: 20
Study Start Date: October 2007
Study Completion Date: January 2009
Primary Completion Date: November 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: minocyline 50 mg or 100 mg PO BID
open label treatment with minocycline low or high dose, 50 mg or 100 mg PO (by mouth) BID (twice a day), added to existing medication regimen for 8 weeks
Drug: Minocycline
50-100 mg PO BID for 8 weeks with an option for a 1 year extension.
Other Name: Solodyn, Dynacin, Arestin, Minocin

Detailed Description:

Fragile X Syndrome (FXS) is the most common known inherited form of mental impairment and is also associated with a range of learning disabilities, neurological problems, such as seizures, and behavioural difficulties. For many individuals with FXS, behavioral difficulties result in severe problems within the family and community, particularly in the form of agitation, temper outbursts, hyperactivity, and aggression. These problems often require a variety of psychopharmacological and behavioural approaches. Although a variety of medications can be helpful in FXS there are no targeted interventions based on molecular abnormalities that have been studied. Defects in dendritic spine formation have been found in the brains of patients with Fragile X, suggesting these structures may represent an anatomical and physiological basis for the cognitive deficits associated with this disorder. Recent research has suggested that minocycline may have a specific benefit in the treatment of FXS. Minocycline is an antibiotic that has been found to inhibit the activity of matrix metallo-proteinase-9 (MMP-9), which is up-regulated in the hippocampus of FMR1 KO (Fragile X Mental Retardation-1 Knockout) mice and may be responsible for the immature dendritic spine profile of hippocampal neurons. Minocycline has recently been used to treat the FXS KO mouse model for Fragile X, and was found to rescue this abnormal phenotype by inducing the formation of mature dendritic spines in FMR1 KO hippocampal neurons, both in vitro and in vivo. Minocycline treated FXS KO mice also performed significantly better in the elevated maze, a cognitive performance test that measures activity and anxiety.

Exciting preclinical effects of minocycline with regard to the FXS disease model have led to this pilot proposal, which is designed to generate preliminary data that could be used to support a larger clinical trial.

The overall hypothesis is that minocycline is a specific molecular targeted treatment for FXS that will display beneficial effects on disruptive behaviour and possibly other associated features of FXS via a reduction in MMP-9 activity.

  Eligibility

Ages Eligible for Study:   13 Years to 35 Years   (Child, Adult)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Diagnosis of FXS by clinical evaluation and confirmed by FMR1-DNA testing with presence of full mutation or mosaicism for the full mutation. Prior DNA testing reports will be accepted, when available.
  • Age between 13 to 35 years inclusive at the time of informed consent.
  • Male or female
  • CGI-Severity Score of 4 or greater, indicative of moderate or greater severity of behavioural problems. This is a 7-point scale of clinical global impression of severity that the clinician fills out after considering all the available information on the patient, including the parent history, the examination in clinic, reports from the school and other sources.
  • Score of 9 or greater on the Aberrant Behaviour Checklist - Irritability Scale (top 50th %-tile). The ABC is a global behaviour checklist implemented for the measurement of drug and other treatment effects in mentally impaired individuals. It is made up of 5 empirically derived dimensions including irritability, lethargy/withdrawal, inappropriate speech, hyperactivity, and stereotypic behaviour based on 58 items that describe various behavioural problems.
  • Availability of parent and/or caregiver for all clinic visits and assessments.
  • English language fluency and reading level of 6th grade or greater in one caregiver.

Exclusion Criteria:

  • Allergy to minocycline.
  • Kidney disease or elevated renal function tests.
  • Liver disease or elevated liver function tests.
  • Participants with neutropenia, anemia, or thrombocytopenia.
  • History of systemic lupus erythematosus or screening anti-nuclear antibody (ANA) titre of >1:40, as minocycline may cause a lupus-like reaction.
  • Individuals who do not have a mother or caregiver who is willing to participate in the clinic visits.
  • Individuals who are pregnant or at risk to become pregnant, specifically sexually active females will be excluded.
  • Presence of persistent psychotic symptoms
  • Subjects with symptom severity likely judged to endanger personal safety or safety of others.
  • History of systemic lupus erythematosus or screening anti-nuclear antibody (ANA) titre of >1:40, as minocycline may cause a lupus-like reaction.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00858689

Locations
Canada, Ontario
Surrey Place Centre
Toronto, Ontario, Canada, M5S 2C2
Sponsors and Collaborators
FRAXA Research Foundation
Fragile X Research Foundation of Canada
Investigators
Principal Investigator: Carlo Paribello, M.D. Fragile X Research Foundation of Canada
  More Information

Additional Information:
Publications:
Responsible Party: FRAXA Research Foundation
ClinicalTrials.gov Identifier: NCT00858689     History of Changes
Other Study ID Numbers: 010308 
Study First Received: March 9, 2009
Results First Received: September 1, 2013
Last Updated: February 16, 2016
Health Authority: Canada: Health Canada

Keywords provided by FRAXA Research Foundation:
Clinical Drug Trial

Additional relevant MeSH terms:
Fragile X Syndrome
Syndrome
Disease
Pathologic Processes
Mental Retardation, X-Linked
Intellectual Disability
Neurobehavioral Manifestations
Neurologic Manifestations
Nervous System Diseases
Sex Chromosome Disorders
Chromosome Disorders
Congenital Abnormalities
Genetic Diseases, Inborn
Genetic Diseases, X-Linked
Heredodegenerative Disorders, Nervous System
Minocycline
Anti-Bacterial Agents
Anti-Infective Agents

ClinicalTrials.gov processed this record on December 09, 2016